Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Dec;5(24):502.
doi: 10.21037/atm.2017.10.25.

Surrogate end points in early prostate cancer clinical states: ready for implementation?

Christos E Kyriakopoulos  1 , Emmanuel S Antonarakis  2
Affiliations
Editorial

Surrogate end points in early prostate cancer clinical states: ready for implementation?

Christos E Kyriakopoulos et al. Ann Transl Med. 2017 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: ES Antonarakis is a paid consultant/advisor to Janssen, Astellas, Sanofi, Dendreon, Medivation, ESSA, AstraZeneca, Clovis and Merck; he has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Tokai, Bristol Myers-Squibb, AstraZeneca, Clovis and Merck; and he is the co-inventor of a biomarker technology that has been licensed to Tokai and Qiagen. CE Kyriakopoulos has no conflicts of interest to declare.

Comment on

References

    1. Scher HI, Morris MJ, Stadler WM, et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 2016;34:1402-18. 10.1200/JCO.2015.64.2702 - DOI - PMC - PubMed
    1. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7. 10.1001/jama.281.17.1591 - DOI - PubMed
    1. Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008;299:2760-9. 10.1001/jama.299.23.2760 - DOI - PMC - PubMed
    1. Antonarakis ES, Chen Y, Elsamanoudi SI, et al. Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. BJU Int 2011;108:378-85. 10.1111/j.1464-410X.2010.09878.x - DOI - PMC - PubMed
    1. Schweizer MT, Zhou XC, Wang H, et al. Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Ann Oncol 2013;24:2881-6. 10.1093/annonc/mdt335 - DOI - PMC - PubMed

LinkOut - more resources